MicroRNAs in lung cancer

Table 1 MicroRNAs in resistance

miRNAs	Target	Drug/ Treatment	R/S	Ref.
miR-9, let-7g	NFκB1	Radiotherapy	S	[66]
miR-34b	BCL2	Radiotherapy	S	[67]
miR-214	N/A; PTEN	Radiotherapy; gefitinib	R	[68,88]
miR-155	FOXO3A; Apaf-1	Radiotherapy; cisplatin	R	[69,78]
miR-210	Stabilizes HIF-1A in normoxia	Radiotherapy	R	[70]
miR-181	N/A	Cisplatin	S	[72]
miR-451	N/A	Cisplatin	S	[73]
miR-98	TP53	Cisplatin	R	[74]
miR-497	BCL2	Multiple drugs	S	[75]
miR-200b	BCL2, XIAP; E2F3	Cisplatin; docetaxel	S	[76,86]
miR-21	PTEN, BCL2	Cisplatin	R	[79]
miR-135a	APC	Paclitaxel	R	[82]
miR-100	Plk1	Docetaxel	S	[85]
miR-337-3p	STAT3, RAP1A	Paclitaxel and	S	[87]
		docetaxel
miR-221, miR-222	P27kip1	TRAIL	R	[91]
miR-130a	MET	TRAIL	S	[92]
miR-212	PED	TRAIL	S	[93]

R: Resistance; S: Sensitivity; XIAP: X-linked inhibitor of apoptosis protein; STAT3: Signal transducer and activator of transcription 3; RAP1A: Ras-related protein Rap-1A; MET: met proto-oncogene (hepatocyte growth factor receptor); PED: Astrocytic phosphoprotein PEA-15; FOXO3A: Forkhead box O3; N/A: Not available; p27kip1: Cyclin-dependent kinase inhibitor 1B.